REV-ERB agonist comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Microsomal glutathione S-transferase 2 is an enzyme that in humans is encoded by the MGST2 gene. The MAPEG (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism) family consists of six human proteins, several of which are involved in the production of leukotrienes and prostaglandin E, important mediators of inflammation. This gene encodes a protein that catalyzes the conjugation of leukotriene A4 and reduced glutathione to produce leukotriene C4.
Chemotherapy, American Cancer Society Hazardous Drug Exposures in Health Care, National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016, National Institute for Occupational Safety and Health International Ototoxicity Management Group (IOMG) - Wikiversity
== Properties and applications == The most distinguishable feature of sequence-controlled polymers is the well-ordered chains composed of different repeating units. By encoding the repeating units, the correspondingly synthesized sequence-controlled polymer can be used for data storage. To modify the monomer with some bioactive moieties, the obtained sequence-controlled polymer is able to treat diseases. The property of sequence control make sequence-controlled polymers an ideal platform to install various kinds of pendants (like drugs, catalyst), whereby diverse functions and applications can be realized.
Oxycodone/aspirin (trade name Percodan) is a combination drug marketed by Endo Pharmaceuticals. It is a tablet containing a mixture of 325 mg (5 grains) of aspirin and 4.8355 mg of oxycodone HCl (equivalent to 4.3346 mg of oxycodone as the free base); it is an opioid/non-opioid combination used to treat moderate to moderately severe pain. The safety of the combination during pregnancy has not been established, although aspirin is generally contraindicated during pregnancy, and the drug has been placed in pregnancy category D. Inactive ingredients include D&C Yellow 10, FD&C Yellow 6, microcrystalline cellulose, and corn starch. Percodan was first marketed by DuPont Pharmaceuticals and prescribed in the United States in 1950. Once a widely prescribed painkiller, it has largely been replaced by alternative oxycodone compounds containing paracetamol (acetaminophen) instead of aspirin, such as Percocet.
Peripherally acting μ-opioid receptor antagonists (PAMORAs) are a class of chemical compounds that are used to reverse adverse effects caused by opioids interacting with receptors outside the central nervous system (CNS), mainly those located in the gastrointestinal tract. PAMORAs are designed to specifically inhibit certain opioid receptors in the gastrointestinal tract and with limited ability to cross the blood–brain barrier. Therefore, PAMORAs do not affect the analgesic effects of opioids within the central nervous system.
Sources: en.wikipedia.org
Substance use disorders are among the more heavily stigmatized health conditions, and negative attitudes are documented among clinicians as well as among the general public. A systematic review of studies of health professionals in Western countries found that negative attitudes towards patients with substance use disorders were common, and that they were associated with poorer communication, less involvement of patients in decisions about their own care, and reduced engagement with treatment. A later systematic review of studies conducted in the United States reported similar findings among practising clinicians and trainees, and found that some educational and contact-based interventions reduced measured stigma; the authors cautioned that the studies were few, varied widely in method, and that none linked measured stigma to patient health outcomes. The arts are used in advocacy and public education about addiction. Artists (particularly those with lived experience of addiction and recovery) use their work to reduce stigma and to reframe addiction as a treatable health condition rather than a moral failing, an approach intended to promote public compassion and shift responses from the criminal-justice system toward the public-health system.
=== 1980s === In February 1981, the company announced a joint venture with Netherlands retail giant Vroom & Dreesmann, which gave its Dutch partner 50% buy-in to many of its retail stores. In 1987, Grace built a can sealant plant in Minhang, China, near Shanghai, becoming the first wholly foreign-owned, private company to do business in The People's Republic of China. In 1989, Grace sold Grace Equipment, an equipment rental company primarily for the petrochemical and construction industry to Companie Francaise de l'Afrique Occidentale (CFAO) of Paris for $305 million. In that same year, Grace did a public offering for 16.6% of its Grace Energy Corporation, which was a company that supplied services and equipment to the oil and gas industry and was involved in oil and gas exploration and development and coal mining as well. The public offering raised approximately $100 million.
Thousands of customers of high street banks including HSBC, Nationwide, Barclays and Virgin Money are affected by payment problems following issues with a system that operates payments between individuals and firms. Princess Anne returns home from hospital following treatment for a head injury and concussion. Prime Minister Rishi Sunak releases a video condemning Andrew Parker, a Reform UK activist, for using a derogatory slur. Sunak mentions that he was called an "f-ing [fucking] Paki" by Parker, stating that "it was too important not to call out". Spain's Civil Guard confirms they have found the body of a British man from London who went missing while hiking in the Pyrenees on 24 June. 29 June – M&S announces plans to launch its own clothing repairs and alterations service starting in August. 30 June Spain's Civil Guard says it has called off its search for Jay Slater, who has been missing in Tenerife since 17 June. Euro 2024: England win 2–1 against Slovakia, taking them through to the quarter-finals. After Slovakia had led 1–0 for most of the game, Jude Bellingham scores and equalises in the fifth minute of the six-minute stoppage time, while captain Harry Kane scores the winning goal in the first minute of extra time.
=== Pharmacokinetics === LGD-4033 showed linear or dose-proportional pharmacokinetics across doses of 0.1 to 1 mg/day over 21 days of administration. Levels of LGD-4033 were 3-fold higher at day 21 compared to day 1, indicating significant accumulation with repeated administration. The mean area-under-curve levels of LGD-4033 on day 21 were 19 ng•day/mL at 0.1 mg/day, 85 ng•day/mL at 0.3 mg/day, and 238 ng•day/mL at 1 mg/day. The elimination half-life of LGD-4033 is 24 to 36 hours. Pharmacokinetic studies of LGD-4033 for purposes of doping detection have also been conducted.
==== Rock cod, reef cod, and coral cod ==== Almost all coral cod, reef cod or rock cod are also in order Perciformes. Most are better known as groupers, and belong to the family Serranidae. Others belong to the Nototheniidae. Two exceptions are the Australasian red rock cod, which belongs to a different order (see below), and the fish known simply as the rock cod and as soft cod in New Zealand, Lotella rhacina, which as noted above actually is related to the true cod (it is a morid cod).
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.